More than temozolomide maintained glioblastoma: the cost of adding tumor-treating fields

Lesen Sie diesen Artikel auf Deutsch.

Takeaway

  • Updated survival outcomes and a model developed based on three mutually exclusive health states show that tumor treatment fields (TTF), added to maintenance temozolomide (TMZ) for patients with glioblastoma (GBM), is an intervention that is not cost-effective.

Why this matters

  • There is a strong concern about the cost-effectiveness for TTF as an intervention for patients with GBM maintained with TMZ despite using an updated cost-effectiveness evaluation using a more flexible potential of the “partitioned survival” model design as well as the latest effectiveness data.

Mochten Sie mehr lesen?

Möchten Sie mehr lesen?

Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.

Sie haben bereits einen Account? Einloggen

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.